Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Colorectal Cancer | Research

Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells

Authors: Li Ding, Zhiping Zhang, Chenhong Zhao, Lei Chen, Zhiqiang Chen, Jie Zhang, Yaxian Liu, Yesen Nie, Yanzhi He, Kai Liao, Xinyue Zhang

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

Ribosomal L1 domain-containing protein 1 (RSL1D1) is a nucleolar protein that is essential in cell proliferation. In the current opinion, RSL1D1 translocates to the nucleoplasm under nucleolar stress and inhibits the E3 ligase activity of HDM2 via direct interaction, thereby leading to stabilization of p53.

Methods

Gene knockdown was achieved in HCT116^p53+/+, HCT116^p53−/−, and HCT-8 human colorectal cancer (CRC) cells by siRNA transfection. A lentiviral expression system was used to establish cell strains overexpressing genes of interest. The mRNA and protein levels in cells were evaluated by qRT-PCR and western blot analyses. Cell proliferation, cell cycle, and cell apoptosis were determined by MTT, PI staining, and Annexin V-FITC/PI double staining assays, respectively. The level of ubiquitinated p53 protein was assessed by IP. The protein-RNA interaction was investigated by RIP. The subcellular localization of proteins of interest was determined by IFA. Protein-protein interaction was investigated by GST-pulldown, BiFC, and co-IP assays. The therapeutic efficacy of RSL1D1 silencing on tumor growth was evaluated in HCT116 tumor-bearing nude mice.

Results

RSL1D1 distributed throughout the nucleus in human CRC cells. Silencing of RSL1D1 gene induced cell cycle arrest at G1/S and cell apoptosis in a p53-dependent manner. RSL1D1 directly interacted with and recruited p53 to HDM2 to form a ternary RSL1D1/HDM2/p53 protein complex and thereby enhanced p53 ubiquitination and degradation, leading to a decrease in the protein level of p53. Destruction of the ternary complex increased the level of p53 protein. RSL1D1 also indirectly decreased the protein level of p53 by stabilizing HDM2 mRNA. Consequently, the negative regulation of p53 by RSL1D1 facilitated cell proliferation and survival and downregulation of RSL1D1 remarkably inhibited the growth of HCT116^p53+/+ tumors in a nude mouse model.

Conclusion

We report, for the first time, that RSL1D1 is a novel negative regulator of p53 in human CRC cells and more importantly, a potential molecular target for anticancer drug development.

Available only for authorised users

Tan BC, Yang CC, Hsieh CL, Chou YH, Zhong CZ, Yung BY, et al. Epigeneitc silencing of ribosomal RNA genes by Mybbp1a. J Biomed Sci. 2012;19(1):57. https://doi.org/10.1186/1423-0127-19-57.CrossRefPubMedPubMedCentral

Andersen JS, Lyon CE, Fox AH, Leung AK, Lam YW, Steen H, et al. Directed proteomic analysis of the human nucleolus. Curr Biol. 2002;12(1):1–11. https://doi.org/10.1016/s0960-9822(01)00650-9.CrossRefPubMed

Pederson T. The plurifunctional nucleolus. Nucleic Acids Res. 1998;26(17):3871–6. https://doi.org/10.1093/nar/26.17.3871.CrossRefPubMedPubMedCentral

Montanaro L, Trere D, Derenzini M. Nucleolus, ribosomes, and cancer. Am J Pathol. 2008;173(2):301–10. https://doi.org/10.2353/ajpath.2008.070752.CrossRefPubMedPubMedCentral

Montanaro L, Trere D, Derenzini M. Changes in ribosome biogenesis may induce cancer by down-regulating the cell tumor suppressor potential. Biochim Biophys Acta. 2012;1825(1):101–10. https://doi.org/10.1016/j.bbcan.2011.10.006.CrossRefPubMed

Dai MS, Lu H. Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem. 2008;105(3):670–7. https://doi.org/10.1002/jcb.21895.CrossRefPubMedPubMedCentral

Miliani de Marval PL, Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget. 2011;2(3):234–8. https://doi.org/10.18632/oncotarget.228.CrossRefPubMedPubMedCentral

Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437(7055):147–53. https://doi.org/10.1038/nature03915.CrossRefPubMed

Liu SJ, Cai ZW, Liu YJ, Dong MY, Sun LQ, Hu GF, et al. Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J Gastroenterol. 2004;10(9):1246–9. https://doi.org/10.3748/wjg.v10.i9.1246.CrossRefPubMedPubMedCentral

10.

Wu Q, Gou Y, Wang Q, Jin H, Cui L, Zhang Y, et al. Downregulation of RPL6 by siRNA inhibits proliferation and cell cycle progression of human gastric cancer cell lines. PLoS One. 2011;6(10):e26401. https://doi.org/10.1371/journal.pone.0026401.CrossRefPubMedPubMedCentral

11.

Bai D, Zhang J, Xiao W, Zheng X. Regulation of the HDM2-p53 pathway by ribosomal protein L6 in response to ribosomal stress. Nucleic Acids Res. 2014;42(3):1799–811. https://doi.org/10.1093/nar/gkt971.CrossRefPubMed

12.

Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23(23):8902–12. https://doi.org/10.1128/MCB.23.23.8902-8912.2003.CrossRefPubMedPubMedCentral

13.

Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4(7):529–33. https://doi.org/10.1038/ncb814.CrossRefPubMed

14.

Guo S, Zhang Z, Tong T. cDNA cloning and function of a new cellular senescence-inhibited gene CSIG. Chin J Biochem Mol Biol. 2003;19(5):612–7. https://doi.org/10.13865/j.cnki.cjbmb.2003.05.016.CrossRef

15.

Li N, Zhao G, Chen T, Xue L, Ma L, Niu J, et al. Nucleolar protein CSIG is required for p33ING1 function in UV-induced apoptosis. Cell Death Dis. 2012;3(3):e283. https://doi.org/10.1038/cddis.2012.22.CrossRefPubMedPubMedCentral

16.

Cheng Q, Yuan F, Lu F, Zhang B, Chen T, Chen X, et al. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. Oncotarget. 2015;6(7):4733–44. https://doi.org/10.18632/oncotarget.2900.CrossRefPubMedPubMedCentral

17.

Cheng Q, Tong TJ, Li Z, Hu SH, Chen DB, Wang SQ, et al. Paradoxical effects of cellular senescence-inhibited gene involved in hepatocellular carcinoma migration and proliferation by ERK pathway and mesenchymal-like markers. Onco Targets Ther. 2019;12:2035–46. https://doi.org/10.2147/OTT.S188449.CrossRefPubMedPubMedCentral

18.

Guo S, Zhang Z, Tong T. Cloning and characterization of cellular senescence-associated genes in human fibroblasts by suppression subtractive hybridization. Exp Cell Res. 2004;298(2):465–72. https://doi.org/10.1016/j.yexcr.2004.04.044.CrossRefPubMed

19.

Ma L, Chang N, Guo S, Li Q, Zhang Z, Wang W, et al. CSIG inhibits PTEN translation in replicative senescence. Mol Cell Biol. 2008;28(20):6290–301. https://doi.org/10.1128/MCB.00142-08.CrossRefPubMedPubMedCentral

20.

Xie N, Ma L, Zhu F, Zhao W, Tian F, Yuan F, et al. Regulation of the MDM2-p53 pathway by the nucleolar protein CSIG in response to nucleolar stress. Sci Rep. 2016;6(1):36171. https://doi.org/10.1038/srep36171.CrossRefPubMedPubMedCentral

21.

Yuan F, Zhang Y, Ma L, Cheng Q, Li G, Tong T. Enhanced NOLC1 promotes cell senescence and represses hepatocellular carcinoma cell proliferation by disturbing the organization of nucleolus. Aging Cell. 2017;16(4):726–37. https://doi.org/10.1111/acel.12602.CrossRefPubMedPubMedCentral

22.

Ma L, Zhao W, Zheng Q, Chen T, Qi J, Li G, et al. Ribosomal L1 domain and lysine-rich region are essential for CSIG/ RSL1D1 to regulate proliferation and senescence. Biochem Biophys Res Commun. 2016;469(3):593–8. https://doi.org/10.1016/j.bbrc.2015.12.004.CrossRefPubMed

23.

Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011;19(3):305–16. https://doi.org/10.1016/j.ccr.2011.01.039.CrossRefPubMedPubMedCentral

24.

Trotman LC, Pandolfi PP. PTEN and p53: who will get the upper hand? Cancer Cell. 2003;3(2):97–9. https://doi.org/10.1016/s1535-6108(03)00022-9.CrossRefPubMed

25.

Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106(9):3207–12. https://doi.org/10.1073/pnas.0808042106.CrossRefPubMedPubMedCentral

26.

Ding L, Sun RN, Zhang XY. Rap2b siRNA significantly enhances the anticancer therapeutic efficacy of adriamycin in a gold nanoshell-based drug/gene co-delivery system. Oncotarget. 2017;8(13):21200–11. https://doi.org/10.18632/oncotarget.15508.CrossRefPubMedPubMedCentral

27.

Zhang X, He Y, Lee KH, Dubois W, Li Z, Wu X, et al. Rap2b, a novel p53 target, regulates p53-mediated pro-survival function. Cell Cycle. 2013;12(8):1279–91. https://doi.org/10.4161/cc.24364.CrossRefPubMedPubMedCentral

28.

Lai WS, Arvola RM, Goldstrohm AC, Blackshear PJ. Inhibiting transcription in cultured metazoan cells with actinomycin D to monitor mRNA turnover. Methods. 2019;155:77–87. https://doi.org/10.1016/j.ymeth.2019.01.003.CrossRefPubMedPubMedCentral

29.

Selth LA, Gilbert C, Svejstrup JQ. RNA immunoprecipitation to determine RNA-protein associations in vivo. CSH Protoc. 2009;(6):pdb.prot5234. https://doi.org/10.1101/pdb.prot5234.

30.

Zhang Z, He Y, Huang Y, Ding L, Chen L, Liu Y, et al. Development and optimization of an in vitro multienzyme synthetic system for production of Kaempferol from Naringenin. J Agric Food Chem. 2018;66(31):8272–9. https://doi.org/10.1021/acs.jafc.8b01299.CrossRefPubMed

31.

Sambrook J, Russell DW. Detection of Protein-Protein Interactions Using the GST Fusion Protein Pulldown Technique. CSH Protoc. 2006;(1):prot3757. https://doi.org/10.1101/pdb.prot3757.

32.

Pratt EP, Owens JL, Hockerman GH, Hu CD. Bimolecular fluorescence complementation (BiFC) analysis of protein-protein interactions and assessment of subcellular localization in live cells. Methods Mol Biol. 2016;1474:153–70. https://doi.org/10.1007/978-1-4939-6352-2_9.CrossRefPubMed

33.

Braithwaite AW, Sturzbecher HW, Addison C, Palmer C, Rudge K, Jenkins JR. Mouse p53 inhibits SV40 origin-dependent DNA replication. Nature. 1987;329(6138):458–60. https://doi.org/10.1038/329458a0.CrossRefPubMed

34.

Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in Cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85(1):375–404. https://doi.org/10.1146/annurev-biochem-060815-014710.CrossRefPubMed

35.

Alexander K, Hinds PW. Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol. 2001;21(11):3616–31. https://doi.org/10.1128/MCB.21.11.3616-3631.2001.CrossRefPubMedPubMedCentral

36.

Bringold F, Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol. 2000;35(3):317–29. https://doi.org/10.1016/s0531-5565(00)00083-8.CrossRefPubMed

37.

Kim EM, Jung CH, Kim J, Hwang SG, Park JK, Um HD. The p53/p21 complex regulates Cancer cell invasion and apoptosis by targeting Bcl-2 family proteins. Cancer Res. 2017;77(11):3092–100. https://doi.org/10.1158/0008-5472.CAN-16-2098.CrossRefPubMed

38.

Barr AR, Cooper S, Heldt FS, Butera F, Stoy H, Mansfeld J, et al. DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nat Commun. 2017;8(1):14728. https://doi.org/10.1038/ncomms14728.CrossRefPubMedPubMedCentral

39.

Liu W, Dai Q, Lu N, Wei L, Ha J, Rong J, et al. LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21(WAF1/Cip1) expression. Biochem Cell Biol. 2011;89(3):287–98. https://doi.org/10.1139/o10-162.CrossRefPubMed

40.

Mikule K, Delaval B, Kaldis P, Jurcyzk A, Hergert P, Doxsey S. Loss of centrosome integrity induces p38-p53-p21-dependent G1-S arrest. Nat Cell Biol. 2007;9(2):160–70. https://doi.org/10.1038/ncb1529.CrossRefPubMed

41.

Zhang DX, Ma DY, Yao ZQ, Fu CY, Shi YX, Wang QL, et al. ERK1/2/p53 and NF-kappaB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis. Eur Rev Med Pharmacol Sci. 2016;20(11):2435–42.PubMed

42.

You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med. 2006;203(7):1657–63. https://doi.org/10.1084/jem.20060353.CrossRefPubMedPubMedCentral

43.

Yan J, Yang S, Tian H, Zhang Y, Zhao H. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer. Cell Death Dis. 2020;11(11):943. https://doi.org/10.1038/s41419-020-03154-w.CrossRefPubMedPubMedCentral

44.

Kong W, Li C, Qi Q, Shen J, Chang K. Cardamonin induces G2/M arrest and apoptosis via activation of the JNK-FOXO3a pathway in breast cancer cells. Cell Biol Int. 2020;44(1):177–88. https://doi.org/10.1002/cbin.11217.CrossRef

45.

Shi XY, Ding W, Li TQ, Zhang YX, Zhao SC. Histone deacetylase (HDAC) inhibitor, Suberoylanilide Hydroxamic acid (SAHA), induces apoptosis in prostate Cancer cell lines via the Akt/FOXO3a signaling pathway. Med Sci Monit. 2017;23:5793–802. https://doi.org/10.12659/msm.904597.CrossRefPubMedPubMedCentral

46.

Park SH, Jang KY, Kim MJ, Yoon S, Jo Y, Kwon SM, et al. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications. Oncotarget. 2015;6(42):44819–31. https://doi.org/10.18632/oncotarget.6264.CrossRefPubMedPubMedCentral

47.

Yang F, Liu WW, Chen H, Zhu J, Huang AH, Zhou F, Gan Y, Zhang YH, Ma L. Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression. J Zhejiang Univ Sci B. 2020;21(1):64–76. https://doi.org/10.1631/jzus.B1900551.

48.

Zeng K, Chen X, Hu X, Liu X, Xu T, Sun H, et al. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation. Oncogene. 2018;37(41):5534–51. https://doi.org/10.1038/s41388-018-0352-7.CrossRefPubMed

49.

Cheok CF, Lane DP. Exploiting the p53 pathway for therapy. CSH Perspect Med. 2017;7(3):a026310. https://doi.org/10.1101/cshperspect.a026310.CrossRef

50.

Gu J, Nie L, Wiederschain D, Yuan ZM. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol Cell Biol. 2001;21(24):8533–46. https://doi.org/10.1128/MCB.21.24.8533-8546.2001.CrossRefPubMedPubMedCentral

51.

Hock AK, Vousden KH. The role of ubiquitin modification in the regulation of p53. Biochim Biophys Acta. 2014;1843(1):137–49. https://doi.org/10.1016/j.bbamcr.2013.05.022.CrossRefPubMed

52.

Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Mol Cell. 2006;21(3):307–15. https://doi.org/10.1016/j.molcel.2006.01.020.CrossRefPubMedPubMedCentral

53.

Gupta A, Shah K, Oza MJ, Behl T. Reactivation of p53 gene by MDM2 inhibitors: a novel therapy for cancer treatment. Biomed Pharmacother. 2019;109:484–92. https://doi.org/10.1016/j.biopha.2018.10.155.CrossRefPubMed

54.

Yu ZK, Geyer RK, Maki CG. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000;19(51):5892–7. https://doi.org/10.1038/sj.onc.1203980.CrossRefPubMed

55.

Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 2004;279(16):16000–6. https://doi.org/10.1074/jbc.M312264200.CrossRefPubMed

56.

Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10(2):138–48. https://doi.org/10.1038/ncb1676.CrossRefPubMedPubMedCentral

57.

Fu W, Ma Q, Chen L, Li P, Zhang M, Ramamoorthy S, et al. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J Biol Chem. 2009;284(21):13987–4000. https://doi.org/10.1074/jbc.M901758200.CrossRefPubMedPubMedCentral

58.

Yee-Lin V, Pooi-Fong W, Soo-Beng AK. Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment. Mini-Rev Med Chem. 2018;18(2):173–83. https://doi.org/10.2174/1389557517666170717125821.CrossRefPubMedPubMedCentral

59.

Jackson MW, Lindstrom MS, Berberich SJ. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J Biol Chem. 2001;276(27):25336–41. https://doi.org/10.1074/jbc.M010685200.CrossRefPubMed

60.

Zhang X, Wang W, Wang H, Wang MH, Xu W, Zhang R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene. 2013;32(22):2782–91. https://doi.org/10.1038/onc.2012.289.CrossRefPubMed

61.

Garcia-Cano J, Sanchez-Tena S, Sala-Gaston J, Figueras A, Vinals F, Bartrons R, et al. Regulation of the MDM2-p53 pathway by the ubiquitin ligase HERC2. Mol Oncol. 2020;14(1):69–86. https://doi.org/10.1002/1878-0261.12592.CrossRefPubMed

62.

Teufel DP, Bycroft M, Fersht AR. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene. 2009;28(20):2112–8. https://doi.org/10.1038/onc.2009.71.CrossRefPubMedPubMedCentral

63.

Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev. 1993;7(12B):2556–64. https://doi.org/10.1101/gad.7.12b.2556.CrossRefPubMed

64.

Chen T, Xue L, Niu J, Ma L, Li N, Cao X, et al. The retinoblastoma protein selectively represses E2F1 targets via a TAAC DNA element during cellular senescence. J Biol Chem. 2012;287(44):37540–51. https://doi.org/10.1074/jbc.M111.260679.CrossRefPubMedPubMedCentral

65.

Saxena A, Rorie CJ, Dimitrova D, Daniely Y, Borowiec JA. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene. 2006;25(55):7274–88. https://doi.org/10.1038/sj.onc.1209714.CrossRefPubMed

66.

Lo D, Lu H. Nucleostemin: another nucleolar “twister” of the p53-MDM2 loop. Cell Cycle. 2010;9(16):3227–32. https://doi.org/10.4161/cc.9.16.12605.CrossRefPubMedPubMedCentral

67.

Kurki S, Peltonen K, Latonen L, Kiviharju TM, Ojala PM, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5(5):465–75. https://doi.org/10.1016/s1535-6108(04)00110-2.CrossRefPubMed

68.

Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1(1):20–6. https://doi.org/10.1038/8991.CrossRefPubMed

69.

Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004;279(43):44475–82. https://doi.org/10.1074/jbc.M403722200.CrossRefPubMed

70.

Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004;23(12):2402–12. https://doi.org/10.1038/sj.emboj.7600247.CrossRefPubMedPubMedCentral

71.

Jin A, Itahana K, O'Keefe K, Zhang Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol. 2004;24(17):7669–80. https://doi.org/10.1128/MCB.24.17.7669-7680.2004.CrossRefPubMedPubMedCentral

72.

Zhang Y, Wang J, Yuan Y, Zhang W, Guan W, Wu Z, et al. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res. 2010;38(19):6544–54. https://doi.org/10.1093/nar/gkq536.CrossRefPubMedPubMedCentral

73.

Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, et al. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 2007;26(35):5029–37. https://doi.org/10.1038/sj.onc.1210327.CrossRefPubMed

74.

Zhou X, Hao Q, Liao J, Zhang Q, Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene. 2013;32(3):388–96. https://doi.org/10.1038/onc.2012.63.CrossRefPubMed

75.

Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M. Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014;20(22):6786–808. https://doi.org/10.3748/wjg.v20.i22.6786.CrossRefPubMedPubMedCentral

76.

Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature. 1997;387(6630):299–303. https://doi.org/10.1038/387299a0.CrossRefPubMed

77.

Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9. https://doi.org/10.1038/387296a0.CrossRefPubMed

78.

Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annu Rev Biochem. 2008;77(1):557–82. https://doi.org/10.1146/annurev.biochem.77.060806.091238.CrossRefPubMed

79.

Wang S, Zhao Y, Aguilar A, Bernard D, Yang CY. Targeting the MDM2-p53 protein-protein interaction for new Cancer therapy: Progress and challenges. CSH Perspect Med. 2017;7(5):a026245. https://doi.org/10.1101/cshperspect.a026245.CrossRef

80.

Levine AJ. Targeting therapies for the p53 protein in Cancer treatments. Annu Rev Cancer Biol. 2019;3(1):21–34. https://doi.org/10.1146/annurev-cancerbio-030518-055455.CrossRef

81.

Mascarenhas J, Lu M, Kosiorek H, Virtgaym E, Xia L, Sandy L, et al. Oral idasanutlin in patients with polycythemia vera. Blood. 2019;134(6):525–33. https://doi.org/10.1182/blood.2018893545.CrossRefPubMedPubMedCentral

82.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–8. https://doi.org/10.1126/science.1092472.CrossRefPubMed

83.

Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133–40. https://doi.org/10.1016/S1470-2045(12)70474-6.CrossRefPubMed

84.

Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barriere C, et al. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014;74(20):5855–65. https://doi.org/10.1158/0008-5472.CAN-14-0799.CrossRefPubMedPubMedCentral

85.

Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem. 2013;56(13):5553–61. https://doi.org/10.1021/jm4005708.CrossRefPubMed

86.

Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem. 2014;57(4):1454–72. https://doi.org/10.1021/jm401753e.CrossRefPubMed

87.

Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem. 2013;56(14):5979–83. https://doi.org/10.1021/jm400487c.CrossRefPubMed

88.

Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, et al. Discovery of a Dihydroisoquinolinone derivative (NVP-CGM097): a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors. J Med Chem. 2015;58(16):6348–58. https://doi.org/10.1021/acs.jmedchem.5b00810.CrossRefPubMed

89.

Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, et al. Phase I trial of the human double minute 2 inhibitor MK-8242 in patients with advanced solid tumors. J Clin Oncol. 2017;35(12):1304–11. https://doi.org/10.1200/JCO.2016.70.7117.CrossRefPubMedPubMedCentral

Title: Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells
Authors: Li Ding
Zhiping Zhang
Chenhong Zhao
Lei Chen
Zhiqiang Chen
Jie Zhang
Yaxian Liu
Yesen Nie
Yanzhi He
Kai Liao
Xinyue Zhang
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colorectal Cancer
Colorectal Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02057-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities

Noncoding RNAs regulate alternative splicing in Cancer

Circular RNA circLMO7 acts as a microRNA-30a-3p sponge to promote gastric cancer progression via the WNT2/β-catenin pathway

Resolvin D1 reduces cancer growth stimulating a protective neutrophil-dependent recruitment of anti-tumor monocytes

IκBα targeting promotes oxidative stress-dependent cell death

Correction to: Knockdown of FOXO3a induces epithelial-mesenchymal transition and promotes metastasis of pancreatic ductal adenocarcinoma by activation of the β-catenin/TCF4 pathway through SPRY2

Keynote webinar | Spotlight on antibody–drug conjugates in cancer